Wang, Chaochen http://orcid.org/0000-0001-5533-1497
Ishizuka, Tomoko http://orcid.org/0000-0002-7416-7474
Tanaka, Masaru http://orcid.org/0009-0008-7302-8692
Matsuo, Koji http://orcid.org/0000-0002-4862-8927
Knight, Hannah http://orcid.org/0000-0002-8379-4381
Harvey, Niamh http://orcid.org/0000-0002-2855-297X
Gillespie-Akar, Liane http://orcid.org/0000-0002-5737-7592
Gibble, Theresa Hunter http://orcid.org/0000-0001-8412-9175
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 7 July 2023
Accepted: 31 October 2023
First Online: 24 November 2023
Declarations
:
: Chaochen Wang, Masaru Tanaka and Koji Matsuo are full-time employees of Eli Lilly Japan K.K., Kobe and minor shareholders of Eli Lilly and Company. Tomoko Ishizuka was a full-time employee of Eli Lilly Japan K.K., Kobe during the conduct of this study and is a current employee of Novo Nordisk Pharma Ltd. Theresa Hunter Gibble is a full-time employee and minor shareholder of Eli Lilly and Company. Hannah Knight, Niamh Harvey and Lianne Gillespie-Akar are employees of Adelphi Real World.
: Data collection by DSP fieldwork teams was conducted in accordance with national market research and privacy regulations, including European Pharmaceutical Market Research Association (EphMRA) and the US Department of Health and Human Services National Institutes of Health, Health Insurance Portability and Accountability Act (HIPAA). This research also obtained ethics approval from the Western Institutional Review Board, study protocol number 1-1238963-1 and performed in accordance with the principles stated in the Declaration of Helsinki. All responses captured on the data collection forms were anonymized to preserve respondent confidentiality. Responses were anonymized before aggregated reporting, the identity of the physicians was blinded, and no patient identifiers were collected. Physicians were compensated in line with fair market rates.